


PHARMACEUTICAL 2020

Aprea Therapeutics Inc. Rank 26 of 358





PHARMACEUTICAL 2020



Aprea Therapeutics Inc. Rank 26 of 358

The relative strengths and weaknesses of Aprea Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aprea Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Aprea Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 258%, being 221% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	133,045
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,062
Liabilities, Non-Current	303
Other Assets	521
Other Compr. Net Income	-2,772
Other Expenses	0
Other Liabilities	0
Other Net Income	1,484
Other Revenues	0
Property and Equipment	42
Research and Development	20,951
Selling, General and Administrative Expense	8,594

Output Variable	Value in 1000 USD
Assets	133,608
Liabilities	9,364
Expenses	29,544
Revenues	0
Stockholders Equity	124,244
Net Income	-28,060
Comprehensive Net Income	-29,446
Economic Capital Ratio	258%

